Apolipoprotein B-containing lipoproteins in renal failure: The relation to mode of dialysis

被引:58
作者
Attman, POA [1 ]
Samuelsson, OG
Moberly, J
Johansson, AC
Ljungman, S
Weiss, LG
Knight-Gibson, C
Alaupovic, P
机构
[1] Sahlgrens Univ Hosp, Dept Nephrol, S-41345 Gothenburg, Sweden
[2] Baxter Healthcare Corp, Div Renal, McGaw Pk, IL USA
[3] Oklahoma Med Res Fdn, Lipid & Lipoprot Lab, Oklahoma City, OK 73104 USA
关键词
chronic renal failure; CAPD; hemodialysis; lipids; apolipoproteins; dyslipidemia;
D O I
10.1046/j.1523-1755.1999.00375.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. The aim of this study was to establish whether there is a differential effect of mode of dialysis, hemodialysis (HD), or continuous ambulatory peritoneal dialysis (CAPD) on the dyslipidemia of renal failure. Methods. The lipoprotein profile was determined in 61 nondiabetic patients on chronic HD (N = 30) and CAPD treatment (N = 31), and in a control group of 27 healthy subjects. The analysis included the measurement of individual apolipoprotein (apo) A- and apo B-containing lipoproteins (LPs) separated by sequential immunoaffinity chromatography. Apo A-containing lipoproteins include lipoprotein A-I with apo A-I and lipoprotein A-I:A-II with apo A-I and apo A-II as the main protein constituents, whereas apo B-containing lipoproteins comprise simple cholesterol-rich lipoprotein B (LP-B), with apo B as the only protein moiety and complex triglyceride (TG)-rich lipoprotein B complex (LP-Bc) particles with apo B, apo A-TI, apo C, and/or apo E as the protein constituents, Results. CAPD patients had significantly higher concentrations of total cholesterol (6.8 vs. 5.1 mmol/liter), low-density lipoprotein (LDL) cholesterol (4.6 vs. 3.2 mmol/liter), TG (2.3 vs. 1.5 mmol/liter). apo B (155.3 vs. 105.7 mg/dl), LP-B (136.0 vs. 91.9 mg/dl), and LP-Bc (19.3 vs. 13.8 mg/dl) than HD patients. Both HD and CAPD patients had significantly higher TG, VLDL cholesterol, apo C-IIII and apo E and significantly lower high-density lipoprotein cholesterol, apo A-III and lipoprotein A-I:A-II levels than control subjects. The distribution of apo C-III in high-density lipoprotein and VLDL-LDL was altered in CAPD patients in comparison with control subjects. This suggests that the removal of TG-rich lipoproteins is less efficient in patients on CAPD. Normotriglyceridemic (NTG; Te less than or equal to 1.7 mmol/liter, 150 mg/dl) CAPD patients had significantly higher levels of TC, LDL cholesterol, apo B, and LP-B than NTG-HD patients. There was little difference in the LP-Bc levels between NTG-CAPD, NTG-HD, and controls. Similarly, hypertriglyceridemic (HTG) CAPD patients had significantly higher TC, LDL cholesterol, apo B, and LP-B levels than HTG-PID patients. The LP-Be levels were significantly increased in HTG-HD and HTG-CAPD patients compared with controls, but the slightly higher levels in the CAPD patients did not differ significantly from the HD group. Conclusion. CAPD and HD patients have a lipoprotein profile characteristic of renal failure. Patients on long-term CAPD have higher levels of cholesterol-rich apo B-containing lipoproteins unrelated to TG levels. Many patients on CAPD also have a substantial elevation of the plasma concentrations of TG-rich LPs. The clinical significance of increased levels of potentially atherogenic LP-B during CAPD remains to be investigated.
引用
收藏
页码:1536 / 1542
页数:7
相关论文
共 42 条
  • [1] DAVID RUBINSTEIN MEMORIAL LECTURE - THE BIOCHEMICAL AND CLINICAL-SIGNIFICANCE OF THE INTERRELATIONSHIP BETWEEN VERY LOW-DENSITY AND HIGH-DENSITY LIPOPROTEINS
    ALAUPOVIC, P
    [J]. CANADIAN JOURNAL OF BIOCHEMISTRY, 1981, 59 (08): : 565 - 579
  • [2] EFFECTS OF LOVASTATIN ON APOA-CONTAINING AND APOB-CONTAINING LIPOPROTEINS - FAMILIES IN A SUBPOPULATION OF PATIENTS PARTICIPATING IN THE MONITORED ATHEROSCLEROSIS REGRESSION STUDY (MARS)
    ALAUPOVIC, P
    HODIS, HN
    KNIGHTGIBSON, C
    MACK, WJ
    LABREE, L
    CASHINHEMPHILL, L
    CORDER, CN
    KRAMSCH, DM
    BLANKENHORN, DH
    [J]. ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (12): : 1906 - 1914
  • [3] ALAUPOVIC P, 1992, NUTR METAB CARDIOVAS, V2, P52
  • [4] Attman PO, 1996, NEPHROL DIAL TRANSPL, V11, P63
  • [5] LIPOPROTEIN METABOLISM AND RENAL-FAILURE
    ATTMAN, PO
    SAMUELSSON, O
    ALAUPOVIC, P
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 21 (06) : 573 - 592
  • [6] Diagnosis and classification of dyslipidemia in renal disease
    Attman, PO
    Samuelsson, O
    Alaupovic, P
    [J]. BLOOD PURIFICATION, 1996, 14 (01) : 49 - 57
  • [7] THE UREMIC DYSLIPIDEMIA - A CROSS-SECTIONAL AND LONGITUDINAL-STUDY
    AVRAM, MM
    GOLDWASSER, P
    BURRELL, DE
    ANTIGNANI, A
    FEIN, PA
    MITTMAN, N
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 20 (04) : 324 - 335
  • [8] BLOEMBERGEN WE, 1995, J AM SOC NEPHROL, V6, P184
  • [9] THE INFLUENCE OF CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS ON PLASMA-LIPOPROTEINS
    BRECKENRIDGE, WC
    RONCARI, DAK
    KHANNA, R
    OREOPOULOS, DG
    [J]. ATHEROSCLEROSIS, 1982, 45 (03) : 249 - 258
  • [10] CHURCHILL DN, 1993, KIDENY INT S40, V43, pS16